Grifols buys 51% of AD vaccine developer Araclon Biotech; Sanofi, Novartis vaccines get thumbs up in EU;

> Spanish group Grifols has bought 51% of University of Zaragoza spinoff Araclon Biotech to safeguard its future; Araclon is developing an Alzheimer's disease vaccine. Press release

> PaxVax's single-dose oral cholera vaccine has been cleared by the U.S. FDA to go into Phase III trials. Article

> Only just visible to the naked eye, house dust mites get everywhere, and HAL Allergy has completed patient enrollment in its Phase II dose range finding study of PURETHAL Mites, its specific immunotherapy for the prevention of persistent allergic rhinitis and rhinoconjunctivitis caused by dust mite allergy. Press release

> Sanofi Pasteur MSD's Proquad measles, mumps, rubella and varicella vaccine has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for use in children and adults from 9 months of age under special circumstances. Article

> The CHMP has announced a positive opinion for Novartis' ($NVS) Menveo meningococcal vaccine, extending its use to children (from 2 years of age), adolescents and adults. Article

> The EMA has withdrawn the marketing authorization for GlaxoSmithKline Biologicals' split virion, inactivated, adjuvanted prepandemic influenza vaccine (H5N1) at GSK's request. Notification (.pdf)

> Next Breath has been listed as a World Health Organization PQS accredited facility for testing nasal sprayed vaccines. Press release

And Finally… The U.K. government is investing in R&D into wool-based packaging to cut temperature-sensitive vaccine losses--and it's more eco-friendly, too! Article

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.